How can pharmaceutical companies meet ambitious sustainability targets while maintaining compliance, product quality, and operational performance? What strategies are organizations using to reduce carbon emissions, optimize water and energy consumption, and build more sustainable facilities? And how are industry leaders navigating evolving regulations; environmental, social, and governance...

Human-in-the-Loop (HITL) is frequently cited as a central control mechanism in AI-supported GxP processes: humans are expected to safeguard outputs generated within artificial intelligence (AI) supported GxP processes through review, approval, or override. However, findings from human factors research, organizational psychology, and the automation bias literature show that human oversight...

How can pharmaceutical organizations successfully scale digital transformation? What does effective Pharma 4.0™ implementation look like in practice? And how are industry leaders applying AI, smart manufacturing, advanced validation, and digital technologies to drive operational excellence while maintaining compliance?

AstraZeneca’s Commercial Cell Therapy Facility in Rockville, Maryland is setting a new benchmark for how pharmaceutical manufacturers can deliver lifesaving therapies while simultaneously advancing sustainability and operational excellence. Recognized as the 2026 ISPE Facility of the Year Awards (FOYA) Social Impact – Unmet Medical Needs Category Winner, the facility demonstrates how...

Expanding active life sciences manufacturing facilities presents unique challenges, where production continuity, regulatory compliance and tight shutdown windows leave little margin for error. Traditional project delivery methods often rely on assumptions and field discovery, increasing the risk of rework, schedule delays and operational disruptions. This blog post explores how digital...

This blog post provides insight into a field-tested case study on how redesigning PLC control logic—rather than adding equipment—increased vial-filling throughput by 14 percent and eliminated a recurring defect-related downtime issue, offering a practical framework other automation engineers can apply to their own lines.

At the 2026 ISPE AI in Life Sciences Summit – Powered by GAMP^®, Lieutenant Seneca Toms, National Expert in Drugs, at the US FDA, reflected on how the life sciences industry should approach AI by drawing lessons from earlier technology transitions.

In today’s highly regulated life sciences environment, computerized systems play a vital role in supporting patient safety, product quality, and data integrity. Whether managing manufacturing operations, clinical data, laboratory processes, pharmacovigilance activities, or quality systems, organizations depend on these technologies to execute critical business processes reliably and...

The future of the pharmaceutical industry will be shaped by more than technology, regulations, and innovation. It will be driven by the people who are developing new skills, embracing new perspectives, and stepping into leadership opportunities that help move the industry forward.

In today’s fast-evolving pharmaceutical landscape, robotics is no longer a futuristic concept, it has become a strategic necessity. From traditional robotic arms and autonomous mobile robots to collaborative robots and emerging humanoid systems, technology adoption is growing at a faster rate. However, the real question is not what is available, but what truly makes a difference for a given...

Cleanroom disinfection is a fundamental component of contamination control in pharmaceutical manufacturing. Although disinfectants are routinely qualified and applied according to validated protocols, their real-world effectiveness depends on multiple interacting factors, including cleaning practices, contact time, surface condition, application technique, personnel performance, environmental...

As antibody-drug conjugates (ADCs) continue to transform cancer treatment, manufacturers face increasing pressure to deliver these highly complex therapies faster, more safely, and with greater reliability. Yet one of the industry's most persistent challenges remains the fragmented supply chain traditionally required to produce ADCs.

Regulatory transitions, product re-registration, marketing-authorization transfers, site changes, Medical Device Directive (93/42/EEC) (MDD)-to- Medical Device Regulation (EU 2017/745) (MDR) migration, open a foreseeable supply-continuity gap: a product can no longer ship under its old regulatory basis but not yet under its new one. The usual response, a flat "three months of bridging stock...

The industry has spent a decade talking about digital transformation. The conversation is no longer about whether to transform, but about how to do it in a way that holds up — technically, operationally, and in front of a regulator. That shift in maturity is what the 2026 ISPE Pharma 4.0™ and Biopharma Conference,...

Artificial intelligence has entered GxP IT validation in two distinct but connected ways—as a tool that helps to perform validation work and as a system that itself requires validation. This blog post explores the dual role of AI and considers how the Validation 4.0 framework can be applied and extended in the AI era.

ISPE professional development training is designed to help pharmaceutical professionals turn regulatory expectations and industry guidance into practical, efficient execution. Pierre Winnepenninckx, a long-standing ISPE member, is one of many highly qualified instructors who bring deep technical expertise and real-world experience to ISPE professional development courses. Through the two...

As the pharmaceutical industry navigates evolving regulatory expectations, emerging technologies, sustainability goals, and increasingly complex global supply networks, professionals need more than presentations and panel discussions. They need opportunities to engage directly with experts, test new ideas, and develop practical solutions they can bring back to their organizations.